×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENTA – enanta pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
07:00 am
enta
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Low
Report
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
2/10
08:05 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/10
07:13 am
enta
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
2/10
07:00 am
enta
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Low
Report
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
2/9
07:06 pm
enta
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
2/9
04:16 pm
enta
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
2/9
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
1/9
08:02 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Date
Time
Symbol
Headline
Impact
2/23
06:02 am
enta
Form EFFECT ENANTA PHARMACEUTICALS
Low
Report
Form EFFECT ENANTA PHARMACEUTICALS
2/13
04:34 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Kowalsky Matthew Paul
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Kowalsky Matthew Paul
2/13
04:33 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luu Brendan
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luu Brendan
2/13
04:30 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Kieffer Tara Lynn
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Kieffer Tara Lynn
2/13
04:29 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Rottinghaus Scott T.
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Rottinghaus Scott T.
2/13
04:28 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Or Yat Sun
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Or Yat Sun
2/13
04:25 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R.
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R.
2/13
08:44 am
enta
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Deep Track Capital, LP
Low
Report
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Deep Track Capital, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Baird likes Enanta's potential in COVID-19, upgrades to Outperform [Seeking Alpha]
11.2%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
TOP News Decliners
3/14
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
-24.0%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: